Live Breaking News & Updates on Arthex Biotech|Page 3
Stay updated with breaking news from Arthex biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs. ....
/PRNewswire/ Arthex Biotech S.A., a pre-clinical-stage biotechnology company pioneering innovative microRNA modulating approaches to diseases with high. ....
/PRNewswire/ Arthex Biotech S.A., a pre-clinical stage biotechnology company pioneering innovative microRNA modulating approaches to diseases with high. ....
Highly competitive process led to successful recommendation to provide 2.5M € as a grant plus up to 11.5 M € as an equity investment in Arthex BiotechProceeds will be used to fund ....
A new 3D model for myotonic dystrophy Myotonic dystrophy is a hereditary degenerative neuromuscular disease that occurs mainly in adults, affecting about 50,000 people only in Spain. Symptoms range from difficulty walking and myotonia (great difficulty in relaxing the contracted muscles) to severe neurological problems, leading to progressive disability that unfortunately puts many of those affected in a wheelchair. This disease is very heterogeneous among patients (age of onset, progression, hereditary transmission, affected muscles), which makes the development of generic treatments especially complex. Currently, drugs against myotonic dystrophy are developed in animal models such as Drosophila, the fruit fly, or in 2D cell cultures. They are later tested in mice and finally in patients. Unfortunately using these approaches, some of the drugs that have been developed have not been able to reach the last stages of clinical trials because they were not effective i ....